Company profile
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Voclosporin | approved | — | 14 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00258713 | phase3 | completed | 2005-09-01 | 2006-07-01 | Aurinia Pharmaceuticals Inc. | A 36-Week Extension to Protocol ISA04-03 |
| NCT02141672 | phase2 | completed | 2014-06-01 | 2016-07-01 | Aurinia Pharmaceuticals Inc. | AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) |
| NCT02949973 | phase2 | completed | 2015-06-01 | 2016-12-01 | Aurinia Pharmaceuticals Inc. | Aurinia Early Urinary Protein Reduction Predicts Response |
| NCT03597464 | phase3 | completed | 2019-09-29 | 2021-10-07 | Aurinia Pharmaceuticals Inc. | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin |
| NCT03021499 | phase3 | completed | 2017-05-17 | 2019-09-24 | Aurinia Pharmaceuticals Inc. | Aurinia Renal Response in Active Lupus With Voclosporin |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 213716 | NDA | AURINIA PHARMACEUTICALS INC | ||||
Loading… | ||||||